ロイコトリエン阻害剤の世界市場2022-2028:モンテルカスト、ザフィルルカスト、プルースト、その他

■ 英語タイトル:Global Leukotriene Inhibitors Market Growth 2022-2028

調査会社LP Information社が発行したリサーチレポート(データ管理コード:LP22DC5019)■ 発行会社/調査会社:LP Information
■ 商品コード:LP22DC5019
■ 発行日:2022年12月
■ 調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
■ 産業分野:医薬品
■ ページ数:123
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後2-3営業日)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥549,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥823,500見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,098,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[ロイコトリエン阻害剤の世界市場2022-2028:モンテルカスト、ザフィルルカスト、プルースト、その他]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

ロイコトリエン阻害剤のグローバル市場規模は、2021年のxxx百万ドルから2028年までにxxx百万ドルに増加すると推定されており、2022年~2028年の年平均成長率(CAGR)はxx%を示しています。COVID-19とロシア・ウクライナ戦争の不確実性を念頭に置いて、さまざまな最終用途部門に対するパンデミックの直接的および間接的な影響を継続的に追跡・分析しています。これらのインサイトは、主要な市場要因としてレポートに含まれています。
ロイコトリエン阻害剤のアジア太平洋市場は、2022年にxxx百万ドルの市場規模が見込まれ、2022年~2028年にかけて約xx%のCAGRで成長すると予想されています。ロイコトリエン阻害剤の米国市場は、2022年にxxx百万ドルの規模があり、2022年~2028年にかけて約xx%のCAGRで成長すると予想されています。ロイコトリエン阻害剤のヨーロッパ市場は、2022年にxxx百万ドルの規模が見込まれ、2022年~2028年にかけて約xx%のCAGRで成長すると予想されています。ロイコトリエン阻害剤の中国市場は、2022年にxxx百万ドルの規模があり、2022年~2028年にかけて約xx%のCAGRで成長すると予想されています。

世界の主要なロイコトリエン阻害剤関連企業としては、Mallinckrodt plc、 Sun Pharmaceutical Industries Ltd、 Novartis AG、 Endo Pharmaceuticals plc、 Zydus Cadila、 Mylan NV、 Mayne Pharma Group Limited、 Teva Pharmaceutical Industries Ltd、 Amneal Pharmaceutical Inc、 Avet Pharmaceuticals Inc、 Aurobindo Pharma、 GSK plc、 Almirall, SA、 Merck & Co., Inc、 Bausch Health、 Sandoz International GmbH、 Pfizer Inc、 AstraZeneca、 Sanofi、 Bayer AG、 McKesson Corporationなどをカバーしています。売上の面では世界最大の2社が2021年にほぼxx%の市場シェアを占めています。

*** レポート範囲 ***

この最新のレポートはすべての重要な側面をカバーしながらロイコトリエン阻害剤のグローバル市場に関する深いインサイトを提供します。これは、市場のマクロな概要から、市場規模、競争環境、開発動向、ニッチ市場、主要な市場ドライバーと課題、バリュー チェーン分析などのミクロの詳細にまで及びます。当レポートは読者がパンデミックおよびロシア・ウクライナ戦争中に世界中でロイコトリエン阻害剤市場シナリオがどのように変化したかを理解できるように定量的データと定性的データの両方を使用して、ロイコトリエン阻害剤のグローバル市場の全体像を提供することを目的としています。

分析の対象となる基準年は2021年で、市場の予測は2022年~2028年までのものです。

*** 市場セグメンテーション ***

この調査ではロイコトリエン阻害剤市場を細分化し、種類別 (モンテルカスト、ザフィルルカスト、プルースト、その他)、用途別 (喘息、COPD、アレルギー性鼻炎、その他)、および地域別 (アジア太平洋、アメリカ州、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分:モンテルカスト、ザフィルルカスト、プルースト、その他

・用途別区分:喘息、COPD、アレルギー性鼻炎、その他

・地域別区分
アメリカ州(アメリカ、カナダ、メキシコ、ブラジル)
APAC/アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
ヨーロッパ(ドイツ、フランス、イギリス、イタリア、ロシア)
中東・アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

*** 各章の紹介 ***
第1章:ロイコトリエン阻害剤の範囲、調査方法など
第2章:エグゼクティブサマリー、世界のロイコトリエン阻害剤市場規模 (販売量、売上) およびCAGR、地域別・種類別・用途別、2017年~2022年までの推移データ、および2028年までの市場予測
第3章:企業別ロイコトリエン阻害剤の販売量、売上、平均価格、グローバル市場シェア、および業界ランキング
第4章:地域別および国別のロイコトリエン阻害剤の販売量と売上(米国、カナダ、ヨーロッパ、中国、日本、韓国、東南アジア、インド、ラテンアメリカ、中東・アフリカなど)
第5/6/7/8章:アメリカ州、アジア太平洋、ヨーロッパ、中東・アフリカの国別、種類別の販売セグメント
第9章:市場動向、市場予測、機会、将来の市場に影響を与える経済動向の分析
第10章:製造コスト構造分析
第11章:販売チャンネル、販売業者および顧客
第12章:地域別、国別、種類別、用途別の世界のロイコトリエン阻害剤市場規模予測
第13章:主要企業の包括的な企業プロファイル
第14章:調査の結果

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:ロイコトリエン阻害剤の年間販売量2017-2028、地域別現状・将来分析
・ロイコトリエン阻害剤の種類別セグメント:モンテルカスト、ザフィルルカスト、プルースト、その他
・ロイコトリエン阻害剤の種類別販売量:2017-2022年の販売量、売上、市場シェア、販売価格
・ロイコトリエン阻害剤の用途別セグメント:喘息、COPD、アレルギー性鼻炎、その他
・ロイコトリエン阻害剤の用途別販売量:2017-2022年の販売量、売上、市場シェア、販売価格

企業別世界のロイコトリエン阻害剤市場
・企業別のグローバルロイコトリエン阻害剤市場データ:2020-2022年の年間販売量、市場シェア
・企業別のロイコトリエン阻害剤の年間売上:2020-2022年の売上、市場シェア
・企業別のロイコトリエン阻害剤販売価格
・主要企業のロイコトリエン阻害剤生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

ロイコトリエン阻害剤の地域別レビュー
・地域別のロイコトリエン阻害剤市場規模2017-2022:年間販売量、売上
・主要国別のロイコトリエン阻害剤市場規模2017-2022:年間販売量、売上
・アメリカ州のロイコトリエン阻害剤販売の成長
・アジア太平洋のロイコトリエン阻害剤販売の成長
・ヨーロッパのロイコトリエン阻害剤販売の成長
・中東・アフリカのロイコトリエン阻害剤販売の成長

アメリカ州市場
・アメリカ州の国別のロイコトリエン阻害剤販売量、売上(2017-2022)
・アメリカ州のロイコトリエン阻害剤の種類別販売量
・アメリカ州のロイコトリエン阻害剤の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋(APAC)市場
・アジア太平洋の国別のロイコトリエン阻害剤販売量、売上(2017-2022)
・アジア太平洋のロイコトリエン阻害剤の種類別販売量
・アジア太平洋のロイコトリエン阻害剤の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のロイコトリエン阻害剤販売量、売上(2017-2022)
・ヨーロッパのロイコトリエン阻害剤の種類別販売量
・ヨーロッパのロイコトリエン阻害剤の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のロイコトリエン阻害剤販売量、売上(2017-2022)
・中東・アフリカのロイコトリエン阻害剤の種類別販売量
・中東・アフリカのロイコトリエン阻害剤の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・ロイコトリエン阻害剤の製造コスト構造分析
・ロイコトリエン阻害剤の製造プロセス分析
・ロイコトリエン阻害剤の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・ロイコトリエン阻害剤の主要なグローバル販売業者
・ロイコトリエン阻害剤の主要なグローバル顧客

地域別のロイコトリエン阻害剤市場予測レビュー
・地域別のロイコトリエン阻害剤市場規模予測(2023-2028)
・アメリカ州の国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・ロイコトリエン阻害剤の種類別市場規模予測
・ロイコトリエン阻害剤の用途別市場規模予測

主要企業分析
Mallinckrodt plc、 Sun Pharmaceutical Industries Ltd、 Novartis AG、 Endo Pharmaceuticals plc、 Zydus Cadila、 Mylan NV、 Mayne Pharma Group Limited、 Teva Pharmaceutical Industries Ltd、 Amneal Pharmaceutical Inc、 Avet Pharmaceuticals Inc、 Aurobindo Pharma、 GSK plc、 Almirall, SA、 Merck & Co., Inc、 Bausch Health、 Sandoz International GmbH、 Pfizer Inc、 AstraZeneca、 Sanofi、 Bayer AG、 McKesson Corporation
・企業情報
・ロイコトリエン阻害剤製品
・ロイコトリエン阻害剤販売量、売上、価格、粗利益(2020-2022)
・主要ビジネス概要
・最新動向

調査の結果

Leukotriene inhibitors, also known as antileukotrienes or leukotriene modifiers, is a medication widely used to treat respiratory diseases associated with an allergic response. It works by preventing leukotrienes, inflammatory mediators from binding to their receptors.
The global market for Leukotriene Inhibitors is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Leukotriene Inhibitors market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Leukotriene Inhibitors market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Leukotriene Inhibitors market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Leukotriene Inhibitors market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Leukotriene Inhibitors players cover Mallinckrodt plc, Sun Pharmaceutical Industries Ltd, Novartis AG, Endo Pharmaceuticals plc and Zydus Cadila, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

[Report Coverage]
This latest report provides a deep insight into the global Leukotriene Inhibitors market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Leukotriene Inhibitors market, with both quantitative and qualitative data, to help readers understand how the Leukotriene Inhibitors market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

[Market Segmentation]
The study segments the Leukotriene Inhibitors market and forecasts the market size by Type (Montelukast, Zafirlukast and Proust), by Application (Asthma, COPD, Allergic Rhinitis and Other), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Montelukast
Zafirlukast
Proust
Other
Segmentation by application
Asthma
COPD
Allergic Rhinitis
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Mallinckrodt plc
Sun Pharmaceutical Industries Ltd
Novartis AG
Endo Pharmaceuticals plc
Zydus Cadila
Mylan NV
Mayne Pharma Group Limited
Teva Pharmaceutical Industries Ltd
Amneal Pharmaceutical Inc
Avet Pharmaceuticals Inc
Aurobindo Pharma
GSK plc
Almirall, SA
Merck & Co., Inc
Bausch Health
Sandoz International GmbH
Pfizer Inc
AstraZeneca
Sanofi
Bayer AG
McKesson Corporation

[Chapter Introduction]
Chapter 1: Scope of Leukotriene Inhibitors, Research Methodology, etc.
Chapter 2: Executive Summary, global Leukotriene Inhibitors market size (sales and revenue) and CAGR, Leukotriene Inhibitors market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Leukotriene Inhibitors sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Leukotriene Inhibitors sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Leukotriene Inhibitors market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Mallinckrodt plc, Sun Pharmaceutical Industries Ltd, Novartis AG, Endo Pharmaceuticals plc, Zydus Cadila, Mylan NV, Mayne Pharma Group Limited, Teva Pharmaceutical Industries Ltd and Amneal Pharmaceutical Inc, etc.
Chapter 14: Research Findings and Conclusion

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Leukotriene Inhibitors Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Leukotriene Inhibitors by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Leukotriene Inhibitors by Country/Region, 2017, 2022 & 2028
2.2 Leukotriene Inhibitors Segment by Type
2.2.1 Montelukast
2.2.2 Zafirlukast
2.2.3 Proust
2.2.4 Other
2.3 Leukotriene Inhibitors Sales by Type
2.3.1 Global Leukotriene Inhibitors Sales Market Share by Type (2017-2022)
2.3.2 Global Leukotriene Inhibitors Revenue and Market Share by Type (2017-2022)
2.3.3 Global Leukotriene Inhibitors Sale Price by Type (2017-2022)
2.4 Leukotriene Inhibitors Segment by Application
2.4.1 Asthma
2.4.2 COPD
2.4.3 Allergic Rhinitis
2.4.4 Other
2.5 Leukotriene Inhibitors Sales by Application
2.5.1 Global Leukotriene Inhibitors Sale Market Share by Application (2017-2022)
2.5.2 Global Leukotriene Inhibitors Revenue and Market Share by Application (2017-2022)
2.5.3 Global Leukotriene Inhibitors Sale Price by Application (2017-2022)
3 Global Leukotriene Inhibitors by Company
3.1 Global Leukotriene Inhibitors Breakdown Data by Company
3.1.1 Global Leukotriene Inhibitors Annual Sales by Company (2020-2022)
3.1.2 Global Leukotriene Inhibitors Sales Market Share by Company (2020-2022)
3.2 Global Leukotriene Inhibitors Annual Revenue by Company (2020-2022)
3.2.1 Global Leukotriene Inhibitors Revenue by Company (2020-2022)
3.2.2 Global Leukotriene Inhibitors Revenue Market Share by Company (2020-2022)
3.3 Global Leukotriene Inhibitors Sale Price by Company
3.4 Key Manufacturers Leukotriene Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Leukotriene Inhibitors Product Location Distribution
3.4.2 Players Leukotriene Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Leukotriene Inhibitors by Geographic Region
4.1 World Historic Leukotriene Inhibitors Market Size by Geographic Region (2017-2022)
4.1.1 Global Leukotriene Inhibitors Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Leukotriene Inhibitors Annual Revenue by Geographic Region
4.2 World Historic Leukotriene Inhibitors Market Size by Country/Region (2017-2022)
4.2.1 Global Leukotriene Inhibitors Annual Sales by Country/Region (2017-2022)
4.2.2 Global Leukotriene Inhibitors Annual Revenue by Country/Region
4.3 Americas Leukotriene Inhibitors Sales Growth
4.4 APAC Leukotriene Inhibitors Sales Growth
4.5 Europe Leukotriene Inhibitors Sales Growth
4.6 Middle East & Africa Leukotriene Inhibitors Sales Growth
5 Americas
5.1 Americas Leukotriene Inhibitors Sales by Country
5.1.1 Americas Leukotriene Inhibitors Sales by Country (2017-2022)
5.1.2 Americas Leukotriene Inhibitors Revenue by Country (2017-2022)
5.2 Americas Leukotriene Inhibitors Sales by Type
5.3 Americas Leukotriene Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Leukotriene Inhibitors Sales by Region
6.1.1 APAC Leukotriene Inhibitors Sales by Region (2017-2022)
6.1.2 APAC Leukotriene Inhibitors Revenue by Region (2017-2022)
6.2 APAC Leukotriene Inhibitors Sales by Type
6.3 APAC Leukotriene Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Leukotriene Inhibitors by Country
7.1.1 Europe Leukotriene Inhibitors Sales by Country (2017-2022)
7.1.2 Europe Leukotriene Inhibitors Revenue by Country (2017-2022)
7.2 Europe Leukotriene Inhibitors Sales by Type
7.3 Europe Leukotriene Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Leukotriene Inhibitors by Country
8.1.1 Middle East & Africa Leukotriene Inhibitors Sales by Country (2017-2022)
8.1.2 Middle East & Africa Leukotriene Inhibitors Revenue by Country (2017-2022)
8.2 Middle East & Africa Leukotriene Inhibitors Sales by Type
8.3 Middle East & Africa Leukotriene Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Leukotriene Inhibitors
10.3 Manufacturing Process Analysis of Leukotriene Inhibitors
10.4 Industry Chain Structure of Leukotriene Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Leukotriene Inhibitors Distributors
11.3 Leukotriene Inhibitors Customer
12 World Forecast Review for Leukotriene Inhibitors by Geographic Region
12.1 Global Leukotriene Inhibitors Market Size Forecast by Region
12.1.1 Global Leukotriene Inhibitors Forecast by Region (2023-2028)
12.1.2 Global Leukotriene Inhibitors Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Leukotriene Inhibitors Forecast by Type
12.7 Global Leukotriene Inhibitors Forecast by Application
13 Key Players Analysis
13.1 Mallinckrodt plc
13.1.1 Mallinckrodt plc Company Information
13.1.2 Mallinckrodt plc Leukotriene Inhibitors Product Offered
13.1.3 Mallinckrodt plc Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Mallinckrodt plc Main Business Overview
13.1.5 Mallinckrodt plc Latest Developments
13.2 Sun Pharmaceutical Industries Ltd
13.2.1 Sun Pharmaceutical Industries Ltd Company Information
13.2.2 Sun Pharmaceutical Industries Ltd Leukotriene Inhibitors Product Offered
13.2.3 Sun Pharmaceutical Industries Ltd Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.2.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.3 Novartis AG
13.3.1 Novartis AG Company Information
13.3.2 Novartis AG Leukotriene Inhibitors Product Offered
13.3.3 Novartis AG Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Novartis AG Main Business Overview
13.3.5 Novartis AG Latest Developments
13.4 Endo Pharmaceuticals plc
13.4.1 Endo Pharmaceuticals plc Company Information
13.4.2 Endo Pharmaceuticals plc Leukotriene Inhibitors Product Offered
13.4.3 Endo Pharmaceuticals plc Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Endo Pharmaceuticals plc Main Business Overview
13.4.5 Endo Pharmaceuticals plc Latest Developments
13.5 Zydus Cadila
13.5.1 Zydus Cadila Company Information
13.5.2 Zydus Cadila Leukotriene Inhibitors Product Offered
13.5.3 Zydus Cadila Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Zydus Cadila Main Business Overview
13.5.5 Zydus Cadila Latest Developments
13.6 Mylan NV
13.6.1 Mylan NV Company Information
13.6.2 Mylan NV Leukotriene Inhibitors Product Offered
13.6.3 Mylan NV Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Mylan NV Main Business Overview
13.6.5 Mylan NV Latest Developments
13.7 Mayne Pharma Group Limited
13.7.1 Mayne Pharma Group Limited Company Information
13.7.2 Mayne Pharma Group Limited Leukotriene Inhibitors Product Offered
13.7.3 Mayne Pharma Group Limited Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Mayne Pharma Group Limited Main Business Overview
13.7.5 Mayne Pharma Group Limited Latest Developments
13.8 Teva Pharmaceutical Industries Ltd
13.8.1 Teva Pharmaceutical Industries Ltd Company Information
13.8.2 Teva Pharmaceutical Industries Ltd Leukotriene Inhibitors Product Offered
13.8.3 Teva Pharmaceutical Industries Ltd Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.8.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.9 Amneal Pharmaceutical Inc
13.9.1 Amneal Pharmaceutical Inc Company Information
13.9.2 Amneal Pharmaceutical Inc Leukotriene Inhibitors Product Offered
13.9.3 Amneal Pharmaceutical Inc Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Amneal Pharmaceutical Inc Main Business Overview
13.9.5 Amneal Pharmaceutical Inc Latest Developments
13.10 Avet Pharmaceuticals Inc
13.10.1 Avet Pharmaceuticals Inc Company Information
13.10.2 Avet Pharmaceuticals Inc Leukotriene Inhibitors Product Offered
13.10.3 Avet Pharmaceuticals Inc Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Avet Pharmaceuticals Inc Main Business Overview
13.10.5 Avet Pharmaceuticals Inc Latest Developments
13.11 Aurobindo Pharma
13.11.1 Aurobindo Pharma Company Information
13.11.2 Aurobindo Pharma Leukotriene Inhibitors Product Offered
13.11.3 Aurobindo Pharma Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Aurobindo Pharma Main Business Overview
13.11.5 Aurobindo Pharma Latest Developments
13.12 GSK plc
13.12.1 GSK plc Company Information
13.12.2 GSK plc Leukotriene Inhibitors Product Offered
13.12.3 GSK plc Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 GSK plc Main Business Overview
13.12.5 GSK plc Latest Developments
13.13 Almirall, SA
13.13.1 Almirall, SA Company Information
13.13.2 Almirall, SA Leukotriene Inhibitors Product Offered
13.13.3 Almirall, SA Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Almirall, SA Main Business Overview
13.13.5 Almirall, SA Latest Developments
13.14 Merck & Co., Inc
13.14.1 Merck & Co., Inc Company Information
13.14.2 Merck & Co., Inc Leukotriene Inhibitors Product Offered
13.14.3 Merck & Co., Inc Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Merck & Co., Inc Main Business Overview
13.14.5 Merck & Co., Inc Latest Developments
13.15 Bausch Health
13.15.1 Bausch Health Company Information
13.15.2 Bausch Health Leukotriene Inhibitors Product Offered
13.15.3 Bausch Health Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Bausch Health Main Business Overview
13.15.5 Bausch Health Latest Developments
13.16 Sandoz International GmbH
13.16.1 Sandoz International GmbH Company Information
13.16.2 Sandoz International GmbH Leukotriene Inhibitors Product Offered
13.16.3 Sandoz International GmbH Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Sandoz International GmbH Main Business Overview
13.16.5 Sandoz International GmbH Latest Developments
13.17 Pfizer Inc
13.17.1 Pfizer Inc Company Information
13.17.2 Pfizer Inc Leukotriene Inhibitors Product Offered
13.17.3 Pfizer Inc Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Pfizer Inc Main Business Overview
13.17.5 Pfizer Inc Latest Developments
13.18 AstraZeneca
13.18.1 AstraZeneca Company Information
13.18.2 AstraZeneca Leukotriene Inhibitors Product Offered
13.18.3 AstraZeneca Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.18.4 AstraZeneca Main Business Overview
13.18.5 AstraZeneca Latest Developments
13.19 Sanofi
13.19.1 Sanofi Company Information
13.19.2 Sanofi Leukotriene Inhibitors Product Offered
13.19.3 Sanofi Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.19.4 Sanofi Main Business Overview
13.19.5 Sanofi Latest Developments
13.20 Bayer AG
13.20.1 Bayer AG Company Information
13.20.2 Bayer AG Leukotriene Inhibitors Product Offered
13.20.3 Bayer AG Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.20.4 Bayer AG Main Business Overview
13.20.5 Bayer AG Latest Developments
13.21 McKesson Corporation
13.21.1 McKesson Corporation Company Information
13.21.2 McKesson Corporation Leukotriene Inhibitors Product Offered
13.21.3 McKesson Corporation Leukotriene Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
13.21.4 McKesson Corporation Main Business Overview
13.21.5 McKesson Corporation Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Leukotriene Inhibitors Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Leukotriene Inhibitors Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Montelukast
Table 4. Major Players of Zafirlukast
Table 5. Major Players of Proust
Table 6. Major Players of Other
Table 7. Global Leukotriene Inhibitors Sales by Type (2017-2022) & (K Units)
Table 8. Global Leukotriene Inhibitors Sales Market Share by Type (2017-2022)
Table 9. Global Leukotriene Inhibitors Revenue by Type (2017-2022) & ($ million)
Table 10. Global Leukotriene Inhibitors Revenue Market Share by Type (2017-2022)
Table 11. Global Leukotriene Inhibitors Sale Price by Type (2017-2022) & (US$/Unit)
Table 12. Global Leukotriene Inhibitors Sales by Application (2017-2022) & (K Units)
Table 13. Global Leukotriene Inhibitors Sales Market Share by Application (2017-2022)
Table 14. Global Leukotriene Inhibitors Revenue by Application (2017-2022)
Table 15. Global Leukotriene Inhibitors Revenue Market Share by Application (2017-2022)
Table 16. Global Leukotriene Inhibitors Sale Price by Application (2017-2022) & (US$/Unit)
Table 17. Global Leukotriene Inhibitors Sales by Company (2020-2022) & (K Units)
Table 18. Global Leukotriene Inhibitors Sales Market Share by Company (2020-2022)
Table 19. Global Leukotriene Inhibitors Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Leukotriene Inhibitors Revenue Market Share by Company (2020-2022)
Table 21. Global Leukotriene Inhibitors Sale Price by Company (2020-2022) & (US$/Unit)
Table 22. Key Manufacturers Leukotriene Inhibitors Producing Area Distribution and Sales Area
Table 23. Players Leukotriene Inhibitors Products Offered
Table 24. Leukotriene Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Leukotriene Inhibitors Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global Leukotriene Inhibitors Sales Market Share Geographic Region (2017-2022)
Table 29. Global Leukotriene Inhibitors Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Leukotriene Inhibitors Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Leukotriene Inhibitors Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global Leukotriene Inhibitors Sales Market Share by Country/Region (2017-2022)
Table 33. Global Leukotriene Inhibitors Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Leukotriene Inhibitors Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Leukotriene Inhibitors Sales by Country (2017-2022) & (K Units)
Table 36. Americas Leukotriene Inhibitors Sales Market Share by Country (2017-2022)
Table 37. Americas Leukotriene Inhibitors Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Leukotriene Inhibitors Revenue Market Share by Country (2017-2022)
Table 39. Americas Leukotriene Inhibitors Sales by Type (2017-2022) & (K Units)
Table 40. Americas Leukotriene Inhibitors Sales Market Share by Type (2017-2022)
Table 41. Americas Leukotriene Inhibitors Sales by Application (2017-2022) & (K Units)
Table 42. Americas Leukotriene Inhibitors Sales Market Share by Application (2017-2022)
Table 43. APAC Leukotriene Inhibitors Sales by Region (2017-2022) & (K Units)
Table 44. APAC Leukotriene Inhibitors Sales Market Share by Region (2017-2022)
Table 45. APAC Leukotriene Inhibitors Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Leukotriene Inhibitors Revenue Market Share by Region (2017-2022)
Table 47. APAC Leukotriene Inhibitors Sales by Type (2017-2022) & (K Units)
Table 48. APAC Leukotriene Inhibitors Sales Market Share by Type (2017-2022)
Table 49. APAC Leukotriene Inhibitors Sales by Application (2017-2022) & (K Units)
Table 50. APAC Leukotriene Inhibitors Sales Market Share by Application (2017-2022)
Table 51. Europe Leukotriene Inhibitors Sales by Country (2017-2022) & (K Units)
Table 52. Europe Leukotriene Inhibitors Sales Market Share by Country (2017-2022)
Table 53. Europe Leukotriene Inhibitors Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Leukotriene Inhibitors Revenue Market Share by Country (2017-2022)
Table 55. Europe Leukotriene Inhibitors Sales by Type (2017-2022) & (K Units)
Table 56. Europe Leukotriene Inhibitors Sales Market Share by Type (2017-2022)
Table 57. Europe Leukotriene Inhibitors Sales by Application (2017-2022) & (K Units)
Table 58. Europe Leukotriene Inhibitors Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa Leukotriene Inhibitors Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa Leukotriene Inhibitors Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Leukotriene Inhibitors Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Leukotriene Inhibitors Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Leukotriene Inhibitors Sales by Type (2017-2022) & (K Units)
Table 64. Middle East & Africa Leukotriene Inhibitors Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa Leukotriene Inhibitors Sales by Application (2017-2022) & (K Units)
Table 66. Middle East & Africa Leukotriene Inhibitors Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Leukotriene Inhibitors
Table 68. Key Market Challenges & Risks of Leukotriene Inhibitors
Table 69. Key Industry Trends of Leukotriene Inhibitors
Table 70. Leukotriene Inhibitors Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Leukotriene Inhibitors Distributors List
Table 73. Leukotriene Inhibitors Customer List
Table 74. Global Leukotriene Inhibitors Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global Leukotriene Inhibitors Sales Market Forecast by Region
Table 76. Global Leukotriene Inhibitors Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Leukotriene Inhibitors Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Leukotriene Inhibitors Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas Leukotriene Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Leukotriene Inhibitors Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC Leukotriene Inhibitors Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Leukotriene Inhibitors Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe Leukotriene Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Leukotriene Inhibitors Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa Leukotriene Inhibitors Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Leukotriene Inhibitors Sales Forecast by Type (2023-2028) & (K Units)
Table 87. Global Leukotriene Inhibitors Sales Market Share Forecast by Type (2023-2028)
Table 88. Global Leukotriene Inhibitors Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global Leukotriene Inhibitors Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global Leukotriene Inhibitors Sales Forecast by Application (2023-2028) & (K Units)
Table 91. Global Leukotriene Inhibitors Sales Market Share Forecast by Application (2023-2028)
Table 92. Global Leukotriene Inhibitors Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global Leukotriene Inhibitors Revenue Market Share Forecast by Application (2023-2028)
Table 94. Mallinckrodt plc Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 95. Mallinckrodt plc Leukotriene Inhibitors Product Offered
Table 96. Mallinckrodt plc Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 97. Mallinckrodt plc Main Business
Table 98. Mallinckrodt plc Latest Developments
Table 99. Sun Pharmaceutical Industries Ltd Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 100. Sun Pharmaceutical Industries Ltd Leukotriene Inhibitors Product Offered
Table 101. Sun Pharmaceutical Industries Ltd Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 102. Sun Pharmaceutical Industries Ltd Main Business
Table 103. Sun Pharmaceutical Industries Ltd Latest Developments
Table 104. Novartis AG Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 105. Novartis AG Leukotriene Inhibitors Product Offered
Table 106. Novartis AG Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 107. Novartis AG Main Business
Table 108. Novartis AG Latest Developments
Table 109. Endo Pharmaceuticals plc Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 110. Endo Pharmaceuticals plc Leukotriene Inhibitors Product Offered
Table 111. Endo Pharmaceuticals plc Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 112. Endo Pharmaceuticals plc Main Business
Table 113. Endo Pharmaceuticals plc Latest Developments
Table 114. Zydus Cadila Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 115. Zydus Cadila Leukotriene Inhibitors Product Offered
Table 116. Zydus Cadila Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 117. Zydus Cadila Main Business
Table 118. Zydus Cadila Latest Developments
Table 119. Mylan NV Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 120. Mylan NV Leukotriene Inhibitors Product Offered
Table 121. Mylan NV Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 122. Mylan NV Main Business
Table 123. Mylan NV Latest Developments
Table 124. Mayne Pharma Group Limited Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 125. Mayne Pharma Group Limited Leukotriene Inhibitors Product Offered
Table 126. Mayne Pharma Group Limited Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 127. Mayne Pharma Group Limited Main Business
Table 128. Mayne Pharma Group Limited Latest Developments
Table 129. Teva Pharmaceutical Industries Ltd Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 130. Teva Pharmaceutical Industries Ltd Leukotriene Inhibitors Product Offered
Table 131. Teva Pharmaceutical Industries Ltd Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 132. Teva Pharmaceutical Industries Ltd Main Business
Table 133. Teva Pharmaceutical Industries Ltd Latest Developments
Table 134. Amneal Pharmaceutical Inc Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 135. Amneal Pharmaceutical Inc Leukotriene Inhibitors Product Offered
Table 136. Amneal Pharmaceutical Inc Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 137. Amneal Pharmaceutical Inc Main Business
Table 138. Amneal Pharmaceutical Inc Latest Developments
Table 139. Avet Pharmaceuticals Inc Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 140. Avet Pharmaceuticals Inc Leukotriene Inhibitors Product Offered
Table 141. Avet Pharmaceuticals Inc Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 142. Avet Pharmaceuticals Inc Main Business
Table 143. Avet Pharmaceuticals Inc Latest Developments
Table 144. Aurobindo Pharma Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 145. Aurobindo Pharma Leukotriene Inhibitors Product Offered
Table 146. Aurobindo Pharma Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 147. Aurobindo Pharma Main Business
Table 148. Aurobindo Pharma Latest Developments
Table 149. GSK plc Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 150. GSK plc Leukotriene Inhibitors Product Offered
Table 151. GSK plc Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 152. GSK plc Main Business
Table 153. GSK plc Latest Developments
Table 154. Almirall, SA Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 155. Almirall, SA Leukotriene Inhibitors Product Offered
Table 156. Almirall, SA Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 157. Almirall, SA Main Business
Table 158. Almirall, SA Latest Developments
Table 159. Merck & Co., Inc Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 160. Merck & Co., Inc Leukotriene Inhibitors Product Offered
Table 161. Merck & Co., Inc Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 162. Merck & Co., Inc Main Business
Table 163. Merck & Co., Inc Latest Developments
Table 164. Bausch Health Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 165. Bausch Health Leukotriene Inhibitors Product Offered
Table 166. Bausch Health Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 167. Bausch Health Main Business
Table 168. Bausch Health Latest Developments
Table 169. Sandoz International GmbH Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 170. Sandoz International GmbH Leukotriene Inhibitors Product Offered
Table 171. Sandoz International GmbH Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 172. Sandoz International GmbH Main Business
Table 173. Sandoz International GmbH Latest Developments
Table 174. Pfizer Inc Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 175. Pfizer Inc Leukotriene Inhibitors Product Offered
Table 176. Pfizer Inc Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 177. Pfizer Inc Main Business
Table 178. Pfizer Inc Latest Developments
Table 179. AstraZeneca Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 180. AstraZeneca Leukotriene Inhibitors Product Offered
Table 181. AstraZeneca Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 182. AstraZeneca Main Business
Table 183. AstraZeneca Latest Developments
Table 184. Sanofi Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 185. Sanofi Leukotriene Inhibitors Product Offered
Table 186. Sanofi Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 187. Sanofi Main Business
Table 188. Sanofi Latest Developments
Table 189. Bayer AG Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 190. Bayer AG Leukotriene Inhibitors Product Offered
Table 191. Bayer AG Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 192. Bayer AG Main Business
Table 193. Bayer AG Latest Developments
Table 194. McKesson Corporation Basic Information, Leukotriene Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 195. McKesson Corporation Leukotriene Inhibitors Product Offered
Table 196. McKesson Corporation Leukotriene Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 197. McKesson Corporation Main Business
Table 198. McKesson Corporation Latest Developments
List of Figures
Figure 1. Picture of Leukotriene Inhibitors
Figure 2. Leukotriene Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Leukotriene Inhibitors Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Leukotriene Inhibitors Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Leukotriene Inhibitors Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Montelukast
Figure 10. Product Picture of Zafirlukast
Figure 11. Product Picture of Proust
Figure 12. Product Picture of Other
Figure 13. Global Leukotriene Inhibitors Sales Market Share by Type in 2021
Figure 14. Global Leukotriene Inhibitors Revenue Market Share by Type (2017-2022)
Figure 15. Leukotriene Inhibitors Consumed in Asthma
Figure 16. Global Leukotriene Inhibitors Market: Asthma (2017-2022) & (K Units)
Figure 17. Leukotriene Inhibitors Consumed in COPD
Figure 18. Global Leukotriene Inhibitors Market: COPD (2017-2022) & (K Units)
Figure 19. Leukotriene Inhibitors Consumed in Allergic Rhinitis
Figure 20. Global Leukotriene Inhibitors Market: Allergic Rhinitis (2017-2022) & (K Units)
Figure 21. Leukotriene Inhibitors Consumed in Other
Figure 22. Global Leukotriene Inhibitors Market: Other (2017-2022) & (K Units)
Figure 23. Global Leukotriene Inhibitors Sales Market Share by Application (2017-2022)
Figure 24. Global Leukotriene Inhibitors Revenue Market Share by Application in 2021
Figure 25. Leukotriene Inhibitors Revenue Market by Company in 2021 ($ Million)
Figure 26. Global Leukotriene Inhibitors Revenue Market Share by Company in 2021
Figure 27. Global Leukotriene Inhibitors Sales Market Share by Geographic Region (2017-2022)
Figure 28. Global Leukotriene Inhibitors Revenue Market Share by Geographic Region in 2021
Figure 29. Global Leukotriene Inhibitors Sales Market Share by Region (2017-2022)
Figure 30. Global Leukotriene Inhibitors Revenue Market Share by Country/Region in 2021
Figure 31. Americas Leukotriene Inhibitors Sales 2017-2022 (K Units)
Figure 32. Americas Leukotriene Inhibitors Revenue 2017-2022 ($ Millions)
Figure 33. APAC Leukotriene Inhibitors Sales 2017-2022 (K Units)
Figure 34. APAC Leukotriene Inhibitors Revenue 2017-2022 ($ Millions)
Figure 35. Europe Leukotriene Inhibitors Sales 2017-2022 (K Units)
Figure 36. Europe Leukotriene Inhibitors Revenue 2017-2022 ($ Millions)
Figure 37. Middle East & Africa Leukotriene Inhibitors Sales 2017-2022 (K Units)
Figure 38. Middle East & Africa Leukotriene Inhibitors Revenue 2017-2022 ($ Millions)
Figure 39. Americas Leukotriene Inhibitors Sales Market Share by Country in 2021
Figure 40. Americas Leukotriene Inhibitors Revenue Market Share by Country in 2021
Figure 41. United States Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 42. Canada Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 43. Mexico Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 44. Brazil Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 45. APAC Leukotriene Inhibitors Sales Market Share by Region in 2021
Figure 46. APAC Leukotriene Inhibitors Revenue Market Share by Regions in 2021
Figure 47. China Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 48. Japan Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 49. South Korea Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 50. Southeast Asia Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 51. India Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 52. Australia Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 53. Europe Leukotriene Inhibitors Sales Market Share by Country in 2021
Figure 54. Europe Leukotriene Inhibitors Revenue Market Share by Country in 2021
Figure 55. Germany Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 56. France Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 57. UK Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 58. Italy Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 59. Russia Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 60. Middle East & Africa Leukotriene Inhibitors Sales Market Share by Country in 2021
Figure 61. Middle East & Africa Leukotriene Inhibitors Revenue Market Share by Country in 2021
Figure 62. Egypt Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 63. South Africa Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 64. Israel Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 65. Turkey Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 66. GCC Country Leukotriene Inhibitors Revenue Growth 2017-2022 ($ Millions)
Figure 67. Manufacturing Cost Structure Analysis of Leukotriene Inhibitors in 2021
Figure 68. Manufacturing Process Analysis of Leukotriene Inhibitors
Figure 69. Industry Chain Structure of Leukotriene Inhibitors
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(LP22DC5019 )"ロイコトリエン阻害剤の世界市場2022-2028:モンテルカスト、ザフィルルカスト、プルースト、その他" (英文:Global Leukotriene Inhibitors Market Growth 2022-2028)はLP Information社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。